Steven Cohen Kezar Life Sciences, Inc. Transaction History

Point72 Asset Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.31 - $3.06 $87,408 - $115,787	-37,839 Reduced 98.53%	563 $1,000
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $120,198 - $280,718	38,402 New	38,402 $120,000
Q2 2022 Aug 15, 2022	SELL	$4.58 - $17.13 $3.01 Million - $11.3 Million	-656,887 Reduced 29.0%	1,608,400 $13.3 Million
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $1.97 Million - $2.93 Million	159,797 Added 7.59%	2,265,287 $37.6 Million
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $15.7 Million - $35.2 Million	2,105,490 New	2,105,490 $35.2 Million
Q2 2019 Aug 14, 2019	SELL	$7.09 - $21.9 $1.46 Million - $4.51 Million	-206,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.83 - $23.75 $1.36 Million - $1.92 Million	81,000 Added 64.8%	206,000 $3.65 Million
Q4 2018 Feb 14, 2019	BUY	$20.21 - $32.9 $2.53 Million - $4.11 Million	125,000 New	125,000 $2.95 Million

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.